Holen Sie sich die Stockscreener-App
4.99
1.96%
-0.10
Handel nachbörslich:
5.01
0.02
+0.40%
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Interim Data from Atopic Dermatitis TrialBURLINGAME, Calif. – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) disclosed key interim data from its randomized, double-blind, placebo-controlled Phase 1 cl - Defense World
Corvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade) - Seeking Alpha
Corvus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRVS) - Defense World
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - AOL
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting (CRVS) - Seeking Alpha
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Stock Traders Buy High Volume of Put Options on Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Corvus stock falls after eczema trial data (CRVS:NASDAQ) - Seeking Alpha
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost - TipRanks
Corvus Pharmaceuticals Shares Surge 7% After Positive Phase 1 Trial Results for Soquelitinib in Atopic Dermatitis - mediahousepress
Corvus Pharmaceuticals stock falls despite promising early trial results - Investing.com
Corvus Pharmaceuticals Announces Interim Data from - GlobeNewswire
Form 8-K Corvus Pharmaceuticals, For: Dec 18 - StreetInsider.com
Corvus Pharma's Atopic Dermatitis Drug Shows Promising 69% Efficacy in Phase 1 Trial Data - StockTitan
Why US Futures Are Rising WednesdayCorvus Pharma (NASDAQ:CRVS), Applied DNA Sciences (NASDAQ:APDN) - Benzinga
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Corvus to share soquelitinib trial data for skin condition By Investing.com - Investing.com Australia
Corvus to share soquelitinib trial data for skin condition - Investing.com India
Stocks to Watch: Worthington Enterprises, Corvus Pharmaceuticals, CommScope Holding - MarketWatch
Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal - MarketWatch
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - The Manila Times
Corvus Pharma Set to Unveil Key Atopic Dermatitis Trial Data for Soquelitinib in December - StockTitan
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Increase in Short Interest - MarketBeat
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% - Yahoo Finance
Trading (CRVS) With Integrated Risk Controls - Stock Traders Daily
Point72 Asset Management L.P. Decreases Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Individual investors are Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) biggest owners and were hit after market cap dropped US$89m - Simply Wall St
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity - The Manila Times
CRVSCorvus Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Corvus Pharma's Cancer Drug Shows Breakthrough Immune Response in Nature Journal Study - StockTitan
Connor Clark & Lunn Investment Management Ltd. Grows Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FY2024 EPS Estimates for CRVS Cut by Cantor Fitzgerald - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC - MarketBeat
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - The Manila Times
Corvus drug shows promise in systemic sclerosis models - Investing.com
Corvus' Soquelitinib Shows Promise in Preventing Systemic Sclerosis Lung Damage in Key Study | CRVS Stock News - StockTitan
Corvus Pharmaceuticals target raised to $13 by Jefferies - Investing.com UK
Corvus Pharmaceuticals: The Market Likes The Story (NASDAQ:CRVS) - Seeking Alpha
Earnings call: Corvus Pharmaceuticals reports Q3 financials and trial updates - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $14.00 Price Target at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst Upgrade - MarketBeat
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Corvus: Q3 Earnings Snapshot - San Antonio Express-News
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Corvus Pharma Reports $41.7M Cash Position, Advances Key Clinical Trials Despite Q3 Loss | CRVS Stock News - StockTitan
Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 1-Year HighHere's Why - MarketBeat
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer - The Manila Times
Corvus' Ciforadenant Shows Promise in Prostate Cancer Treatment, Doubles Response Rate | CRVS Stock News - StockTitan
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
Corvus Pharmaceuticals (CRVS) Scheduled to Post Earnings on Tuesday - MarketBeat
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):